Teva Seeks New CFO as It Faces High Debt Levels, Opioid Litigation - WSJ
Meet The New Teva: 8% Global Generics Share, 300 ANDAs, 1,500 Launches :: Scrip
Investors sue Teva over $41B Actavis deal - Drug Delivery Business
Earnings Preview: It's a mixed bag for Teva Pharma in Q3 | AlphaStreet
Teva Stock Skyrockets After Inking North Of $4 Billion In Opioid Settlements | Investor's Business Daily
Buy Teva Pharmaceuticals amid positive news, Bernstein says
Teva Pharmaceutical Industries — 9 Portfolio companies, 10 Investments, Team — Unicorn Nest
6 Reasons I've Been Aggressively Buying Teva Pharmaceutical Industries | The Motley Fool
TEVA Pharmaceuticals sells Forest facility to private investor | WSET
Teva completes $40b purchase of Allergan generics arm | The Times of Israel
Teva Investor Relations by Teva Pharmaceuticals USA, Inc.
Report: Teva settles investor lawsuit for $420M - www.israelhayom.com
Teva Stock: Teva Guides To Its First Year Of Growth Since 2017, But There's A Caveat | Investor's Business Daily
Teva Pharmaceutical to Nominate Four New Directors - WSJ
Teva dispenses $2.6 million to resolve ERISA claims | Pensions & Investments
Five Considerations After Teva Pharmaceuticals' Q3 Report (NYSE:TEVA) | Seeking Alpha
Teva Pharmaceutical Stock Could Double | Barron's
Teva Bonds: 8.8% Yield To Maturity Understates Upside | Nasdaq
Teva Pharmaceuticals has acquired success with Actavis Generics | World Finance
Teva Reports Second Quarter 2022 Financial Results | Business Wire
Investors question green tint of Teva's $5bn sustainability bond | Financial Times
